Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Toyoko Harada"'
Publikováno v:
Oncology Letters. 14:3349-3356
Gimeracil or 5-chloro-2,4-dihydroxypyridine (CDHP) enhances the antitumor effects of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase (DPD), which is involved in the degradation of 5-FU. CDHP, as part of a combination therapy, was
Autor:
KOJI HARADA1 harako@yamaguchi-u.ac.jp, TOYOKO HARADA1, TARANNUM FERDOUS1, TAKANORI TAKENAWA1, YOSHIYA UEYAMA1
Publikováno v:
Molecular Medicine Reports. 2015, Vol. 12 Issue 1, p31-36. 6p.
Publikováno v:
Clinical and Experimental Medicine. 17:45-50
Stathmin 1 is an oncoprotein that regulates cell cycle by modulating microtubule dynamics and can cause uncontrolled cell proliferation in mutated state. The present study examined stathmin 1 expression in 49 patients with oral squamous cell carcinom
Publikováno v:
Molecular Medicine Reports
The use of stem cells represents a promising approach for the treatment of bone defects. However, successful treatments rely upon the availability of cells that are easily obtained and that appropriately differentiate into osteoblasts. The tongue pot
Publikováno v:
Toukeibu Gan. 39:317-324
Publikováno v:
Toukeibu Gan. 37:536-541
Publikováno v:
International journal of oncology. 49(1)
Cancer cells show enhanced glucose consumption and lactate production even in the presence of abundant oxygen, a phenomenon known as the Warburg effect, which is related to tumor proliferation, progression and drug-resistance in cancers. Hypoxia-indu
Publikováno v:
International journal of oncology. 43(1)
Metronomic chemotherapy is based on administration of anticancer agents at low-doses at close regular intervals with no prolonged breaks, and aims to inhibit vascular endothelial cells as well as tumor cells. Recently, it was suggested that metronomi
Publikováno v:
Oncology Letters; Sep2017, Vol. 14 Issue 3, p3349-3356, 8p
Publikováno v:
International Journal of Oncology; Jul2016, Vol. 49 Issue 1, p276-284, 9p